Skip to main content
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA — Investor Relations & Filings

Ticker · VRTX ISIN · US92532F1003 LEI · 54930015RAQRRZ5ZGJ91 US Manufacturing
Filings indexed 2,379 across all filing types
Latest filing 2023-10-06 Regulatory Filings
Country US United States of America
Listing US VRTX

About VERTEX PHARMACEUTICALS INC / MA

https://www.vrtx.com/

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to discover, develop, and commercialize transformative medicines for serious diseases. The company is a leader in the field of cystic fibrosis (CF), having developed multiple therapies that treat the underlying cause of the disease for a significant portion of patients. Beyond its focus on CF, Vertex is advancing a research and development pipeline that includes potential treatments for other serious conditions such as sickle cell disease, beta-thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, and type 1 diabetes. The company's strategy is centered on a deep understanding of human biology to address the root cause of illness.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-10-06 English
FORM 4 SUBMISSION
Director's Dealing
2023-10-05 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 3, 2023, reporting the appointment of a new board member, Michel Lagarde, to the company's board of directors effective October 5, 2023. The content focuses on the departure and election of directors and officers, detailing the new director's background and compensation. There are no financial statements or earnings data, nor is this a report or announcement of a financial report. The primary subject is a change in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is 4582 characters, which is consistent with a typical 8-K filing for management changes. Therefore, the appropriate classification is MANG with high confidence.
2023-10-05 English
FORM 4 SUBMISSION
Director's Dealing
2023-10-03 English
Regulatory Filings 2023
Regulatory Filings
2023-10-03 English
Regulatory Filings 2023
Regulatory Filings
2023-10-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.